Tailwinds' Take: more positive data just before they meet with the FDA. Important notes from the data include potential "Phase 0" detection and the possibility that Cchek can be used for ongoing maintenance of breast cancer survivors. While the...
This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least, that's what has traditionally happened. There always remains the risk of finding your stockings filled...
Tailwinds' Take: expecting more positive data out of Cchek. Big meeting with FDA in December will tell us how quickly this product can come to market. With positive results in two cancer indications with no alternative quality early stage...
SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that its two presentations at the 33rd Annual Meeting of The Society for...
October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from several disastrous meltdowns. These include Black Monday in 1987 when the market lost 23% in...
Tailwinds' Take: Anixa continues to demonstrate nothing but very positive results, so expect more from this presentation. We continue to believe the risk / reward of ANIX is very compelling as data continues to be positive on both products...
In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December. These are important events as the FDA will review data submitted before even agreeing to...
Tailwinds' Take: very positive development getting Cchek in front of the FDA for preliminary discussions, especially how quickly the meeting was accepted. With two programs on track, ANIX is very undervalued by the markets. SAN JOSE, Calif., Oct. 24, 2018...
Tailwinds' Take: although this is a minor delay from previous (best case) guidance, it is still fabulous news that Anixa expects to have a CAR-T drug in humans next summer. We expect to see the stock at much higher...
Tailwinds' Take: This is outstanding data. The detection of cancer remains in line with prior releases, but the ability to detect benign versus malignant is huge! Almost 80% of biopsies are unnecessary. Removing over 50% of these will be...